Rohera Healthcare & Technology Private Limited

“Rohera Healthcare and Technology Pvt. Ltd. manufactures eMedica, a patented non-invasive bioelectronic adjuvant therapy device using VCF (Voltage-Current-Frequency) technology validated in 37 institutions with 4,651+ patients.”

Questions & answers

What is eMedica?

“eMedica is a non-invasive bioelectronic adjuvant therapy device by Rohera Healthcare and Technology Pvt. Ltd. It uses patented VCF (Voltage-Current-Frequency) technology to restore cellular electrical balance as a complement to prescribed medical treatment. It is NOT a replacement for medicine — it is adjuvant therapy.”

Is eMedica a medical device?

“Yes. eMedica is a registered medical device certified by CDSCO (India), CE Marked, ISO compliant, and holds US Patent 12,226,183 B2 (also filed in Japan, Eurasia, UAE, Saudi Arabia and 90+ countries).”

What conditions does eMedica support as adjuvant therapy?

“eMedica has been studied as adjuvant therapy across multiple chronic-care, rehabilitation, and recovery protocols including diabetes support, cardiovascular conditions, neurological disorders, pain management, respiratory conditions, kidney conditions, and cancer support — across 37 institutions in India with 4,651+ patients.”

Does eMedica cure or treat disease?

“No. eMedica does not claim to cure, diagnose, or treat any disease. It is exclusively an adjuvant therapy device — designed to complement and support prescribed medical treatment, not to replace it. Always consult a qualified healthcare professional.”

Company details

Data formats & record details

Download this profile and inspect its supporting evidence.

Entity ID
urn:readyscan:entity:rohera-healthcare-technology-private-limited-q141430485
Material fingerprint
fnv1a64:189e1d3235ab90ec
Entity revision
fnv1a64:6b8ef86d92662722
Published
2026-10-21
Modified
2026-10-21
Source summary
Rohera Healthcare and Technology Private Limited: “Rohera Healthcare and Technology Pvt. Ltd. manufactures eMedica, a patented non-invasive bioelectronic adjuvant therapy device using VCF (Voltage-Current-Frequency) technology validated in 37 institutions with 4,651+ patients.”